Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab

Frontiers in Immunology

Immunology

Yi-Hua Jan¹  Yun-Tzu Lin²  Hung-Chang Wu³  Yu-Hsuan Kuo⁴  Chien-Feng Li⁵ 

[1] ACT Genomics Co. Ltd., Taipei, Taiwan;Department of Oncology, Chi-Mei Medical Center, Tainan, Taiwan;Department of Oncology, Chi-Mei Medical Center, Tainan, Taiwan;College of Pharmacy and Science, Chia Nan University, Tainan, Taiwan;Department of Oncology, Chi-Mei Medical Center, Tainan, Taiwan;College of Pharmacy and Science, Chia Nan University, Tainan, Taiwan;Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan;Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan;Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan;Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan;National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan;

关键词: SMARCA4;    BRG1;    SWI/SNF;    lung cancer;    non-small cell lung carcinoma;    check-point inhibitors;    nivolumab;   

DOI  :  10.3389/fimmu.2023.1131448

 received in 2022-12-25, accepted in 2023-03-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.

【 授权许可】

Unknown   
Copyright © 2023 Lin, Li, Wu, Jan and Kuo